GSK and XenoPort receive FDA approval for Horizant® for postherpetic neuralgia
7 June 2012 | By GlaxoSmithKline
The US FDA has approved Horizant® (gabapentin enacarbil)...
List view / Grid view
News
BASF subsidiary Metanomics Health launches MetaMap®Tox
6 June 2012 | By BASF
Metanomics Health GmbH is launching MetaMap®Tox...
Roche’s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
6 June 2012 | By Roche
Data announced from the ADACTA study...
ORENCIA® (abatacept) demonstrates comparable efficacy to Humira® (adalimumab)
6 June 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company have announced the results of AMPLE...
Novartis Phase III study showed 62% of patients with most severe form of childhood arthritis were symptom-free with ACZ885 treatment
6 June 2012 | By Novartis
New data announced from two trials...
William Kaelin Jr. elected to Lilly Board of Directors
6 June 2012 | By Eli Lilly and Company
The Board of Directors of Eli Lilly and Company has elected William G. Kaelin Jr., M.D. as a new member...
Abbott presents Phase 3 study results for investigational use of HUMIRA®
6 June 2012 | By Abbott
First Phase 3 study to evaluate an anti-TNF in patients with non-radiographic axial spondyloarthritis...
Abbott announces 10-Year data evaluating HUMIRA® (Adalimumab)
6 June 2012 | By Abbott
Abbott announced results from two long-term, open-label studies...
FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
New Phenomenex size exclusion columns for biomolecules deliver significant advancement in resolving power
6 June 2012 | By Phenomenex Inc
Phenomenex Inc., introduces Yarra™...
Catalent increased sterile fill-finish manufacturing capacity at its Research Triangle Park facility in NC
5 June 2012 | By Catalent Pharma Solutions
Completion of a newly renovated aseptic fill-finish manufacturing facility announced...
Merck receives complete response letter from U.S. FDA for investigational medicine ridaforolimusr
5 June 2012 | By Merck
Ridaforolimus is an investigational oral mTOR inhibitor...
Abbott announces initiation of Phase 3 study of Elagolix in patients with endometriosis
5 June 2012 | By Abbott
Abbott have announced the initiation of a pivotal Phase 3 clinical trial...
Abbott introduces Ensure Clear™ to help adults fill dietary gap
5 June 2012 | By Abbott
One in three adults doesn’t obtain all of the daily nutrients they need to support optimal health...
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
